MyoKardia Profile

47.70
USD 0.55  1.14%
40%
80%

MyoKardia exotic insider transaction detected

MyoKardia insider trading alert for general transaction of stock option (right to buy) by Robert McDowell, the corporate stakeholder, on April 11, 2018. This event was filed by Myokardia Inc with SEC on 2015-10-28. Initial filing of beneficial ownership - SEC Form 3 [view details]   

MyoKardia Summary

MyoKardia (MYOK) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 102 people. MyoKardia is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.86 B. MyoKardia conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 35.97 M outstanding shares of which 1.55 M shares are now shorted by private and institutional investors with about 4.63 trading days to cover. MyoKardia currently holds about 223.69 M in cash with (54.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22.
Check MyoKardia Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 47.7HorizonTargetOdds Above 47.7
33.82%30 days 47.70 65.89%
Based on normal probability distribution, the odds of MyoKardia to move above current price in 30 days from now is about 65.89% (This MyoKardia probability density function shows the probability of MyoKardia Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.4 M263 M
Wellington Management Group LlpCommon Shares3.3 M163.3 M
View MyoKardia Diagnostics

Selected MyoKardia Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

MyoKardia Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
56 
Equity ratings for MyoKardia are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. MyoKardia operates under Biotechnology classification in USA and traded on NASDAQ. It employs 102 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameMyoKardia
CEO and President and DirectorTassos GianakakosView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address333 Allerton Avenue
ExchangeNASDAQ
CIK Number01552451.0
CUSIP62857M105
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.myokardia.com
Contact Number650 741 0900
CurrencyUSD - US Dollar

Recommendations

MyoKardia Analyst Recommendations
Target PriceAdvice# of Analysts
26.67Strong Buy3Odds
MyoKardia current and past analyst recommendations published by number of research institutions as well as average analyst consensus
MyoKardia Analyst Advice  

Earnings

MyoKardia Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.31March 17, 2017
MyoKardia normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

MyoKardia Corporate Directors
Eric Topol Independent Director
Sunil Agarwal Independent Director
Mark Perry Independent Director
Please see also Stocks Correlation. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.